Literature DB >> 30929157

Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells.

Jian-Ning Yao1, Xue-Xiu Zhang1, Yan-Zhen Zhang1, Jia-Heng Li2, Dong-Yao Zhao1, Bing Gao1, Hai-Ning Zhou1, Shi-Lin Gao1, Lian-Feng Zhang3.   

Abstract

Background Gastric cancer (GC) is the second most common cause of cancer-related death worldwide. Novel anticancer drugs against gastric cancer are urgently needed. Methods Compound 10 was designed and synthesized via a molecular hybridization strategy based on the natural product formononetin. It was evaluated for their antiproliferative activity against three gastric cancer cell lines (SGC7901, MKN45 and MGC803). Results Derivative 10 displayed potently antiproliferative activity with an IC50 value of 1.07 μM against SGC7901 cells. Derivative 10 could inhibit the growth and migration against gastric cancer SGC7901 cells through the Wnt/β-Catenin and AKT/mTOR pathways. From the in vivo expremints, it could effectively inhibited SGC7901 xenograft tumor growth in vivo without significant loss of the body weight. Conclusion Derivative 10 is an novel antitumor agent with potential for further clinical applications to treat gastric cancer. Graphical abstract.

Entities:  

Keywords:  Formononetin; Gastric cancer; Growth; Migration; SGC7901

Mesh：

Substances：

Year:  2019        PMID： 30929157     DOI： 10.1007/s10637-019-00767-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  37 in total

1.  Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.

Authors:  J Chen; J Zeng; M Xin; W Huang; X Chen
Journal:  Horm Metab Res       Date:  2011-09-19       Impact factor: 2.936

2.  EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway.

Authors:  Hongli Li; Baogang Zhang; Yuqing Liu; Chonggao Yin
Journal:  Med Oncol       Date:  2014-08-14       Impact factor: 3.064

3.  Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1.

Authors:  Kevin J Bitterman; Rozalyn M Anderson; Haim Y Cohen; Magda Latorre-Esteves; David A Sinclair
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

4.  Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.

Authors:  Ticiano P Barbosa; Suervy C O Sousa; Francianne M Amorim; Yara K S Rodrigues; Priscilla A C de Assis; John P A Caldas; Márcia R Oliveira; Mário L A A Vasconcellos
Journal:  Bioorg Med Chem       Date:  2011-06-01       Impact factor: 3.641

5.  A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide.

Authors:  Yu Feng; Jiahui Wu; Lei Chen; Chen Luo; Xu Shen; Kaixian Chen; Hualiang Jiang; Dongxiang Liu
Journal:  Anal Biochem       Date:  2009-08-13       Impact factor: 3.365

6.  Formononetin inhibits enterovirus 71 replication by regulating COX- 2/PGE₂ expression.

Authors:  Huiqiang Wang; Dajun Zhang; Miao Ge; Zhuorong Li; Jiandong Jiang; Yuhuan Li
Journal:  Virol J       Date:  2015-03-01       Impact factor: 4.099

7.  Formononetin inhibits lipopolysaccharide-induced release of high mobility group box 1 by upregulating SIRT1 in a PPARδ-dependent manner.

Authors:  Jung Seok Hwang; Eun Sil Kang; Sung Gu Han; Dae-Seog Lim; Kyung Shin Paek; Chi-Ho Lee; Han Geuk Seo
Journal:  PeerJ       Date:  2018-01-03       Impact factor: 2.984

8.  Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.

Authors:  Yalin Wang; Yan Zhou; Zhongnan Zheng; Juntao Li; Yuting Yan; Wei Wu
Journal:  Cell Death Dis       Date:  2018-11-14       Impact factor: 8.469

9.  Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.

Authors:  Saman Khan; Ali Mohammed Malla; Atif Zafar; Imrana Naseem
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

10.  Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells.

Authors:  Xi Chen; Xiaoming Chen; Xi Zhang; Li Wang; Peihai Cao; Vinothkumar Rajamanickam; Chao Wu; Huiping Zhou; Yuepiao Cai; Guang Liang; Yi Wang
Journal:  Redox Biol       Date:  2018-12-07       Impact factor: 11.799
View more
  7 in total

1.  Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer.

Authors:  Xinyou Yu; Feng Gao; Wei Li; Li Zhou; Wenbin Liu; Ming Li
Journal:  J Exp Clin Cancer Res       Date:  2020-04-10

2.  QiDiTangShen Granules Activate Renal Nutrient-Sensing Associated Autophagy in db/db Mice.

Authors:  Xiangming Wang; Li Zhao; Amrendra K Ajay; Baihai Jiao; Xianhui Zhang; Chunguo Wang; Xue Gao; Zhongyu Yuan; Hongfang Liu; Wei Jing Liu
Journal:  Front Physiol       Date:  2019-10-01       Impact factor: 4.566

Review 3.  The Potential Anticancer Activity of Phytoconstituents against Gastric Cancer-A Review on In Vitro, In Vivo, and Clinical Studies.

Authors:  Sylwia Nakonieczna; Aneta Grabarska; Wirginia Kukula-Koch
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

Review 4.  Targeting the Wnt/β-catenin signaling pathway in cancer.

Authors:  Ya Zhang; Xin Wang
Journal:  J Hematol Oncol       Date:  2020-12-04       Impact factor: 17.388

5.  Formononetin ameliorates IL‑13‑induced inflammation and mucus formation in human nasal epithelial cells by activating the SIRT1/Nrf2 signaling pathway.

Authors:  Juanjuan Huang; Xianfeng Chen; Aihua Xie
Journal:  Mol Med Rep       Date:  2021-09-30       Impact factor: 3.423

Review 6.  Formononetin: A Pathway to Protect Neurons.

Authors:  Xiaoyu Ma; Juejin Wang
Journal:  Front Integr Neurosci       Date:  2022-07-13

Review 7.  Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.

Authors:  Eleni Sflakidou; George Leonidis; Eirini Foroglou; Christos Siokatas; Vasiliki Sarli
Journal:  Molecules       Date:  2022-10-06       Impact factor: 4.927
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.